Literature DB >> 25916084

Perioperative administration of Daikenchuto (TJ-100) reduces the postoperative paralytic ileus in patients with pancreaticoduodenectomy.

Ken-Ichi Okada, Manabu Kawai, Seiko Hirono, Motoki Miyazawa, Atsushi Shimizu, Yuji Kitahata, Hiroki Yamaue.   

Abstract

BACKGROUND/AIMS: No study has reported whether perioperative administration of Daikenchuto (TJ-100) reduced paralytic ileus after pancreaticoduodenectomy (PD).
METHODOLOGY: Forty-five consecutive patients that were scheduled to undergo PD at Wakayama Medical University Hospital between August 2010 and August 2011 were enrolled in this study including the first cohort (n = 15) as the control group and the subsequent cohort (n = 30) as the TJ-100 group. This trial was registered at UMIN-CTR ID# 000005056.
RESULTS: Postoperative paralytic ileus occurred more frequently in the control group (73.3% of the control group and 20.0% of the TJ-100 group; p = 0.001). The first passages of flatus significantly improved earlier in the TJ-100 group than in the control group (p = 0.014). A multiple cytokine assay of the drainage and serum showed that IL-9 and IL-10 in the drainage was significantly higher on postoperative day 1 in the TJ-100 group. There were no complications associated with the preoperative administration of TJ-100 before surgery, and no significant differences were observed between the two groups in the incidence of postoperative Gradel-2 diarrhea (CTCAE4.0).
CONCLUSIONS: Perioperative administration of TJ-100 was feasible and reduced the incidence of paralytic ileus in PD, and further randomized controlled trials should be conducted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25916084

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Transition of serum cytokines following pancreaticoduodenectomy: A subsidiary study of JAPAN-PD.

Authors:  Hiromichi Maeda; Ken-Ichi Okada; Tsutomu Fujii; Mari S Oba; Manabu Kawai; Seiko Hirono; Yasuhiro Kodera; Masayuki Sho; Takahiro Akahori; Yasuhiro Shimizu; Yoshiyasu Ambo; Naru Kondo; Yoshiaki Murakami; Jiro Ohuchida; Hidetoshi Eguchi; Hiroaki Nagano; Junichi Sakamoto; Hiroki Yamaue
Journal:  Oncol Lett       Date:  2018-09-07       Impact factor: 2.967

2.  No Significant Effect of Daikenchuto (TJ-100) on Peritoneal IL-9 and IFN-γ Levels After Pancreaticoduodenectomy.

Authors:  Hiromichi Maeda; Ken-Ichi Okada; Tsutomu Fujii; Mari S Oba; Manabu Kawai; Seiko Hirono; Yasuhiro Kodera; Masayuki Sho; Takahiro Akahori; Yasuhiro Shimizu; Yoshiyasu Ambo; Naru Kondo; Yoshiaki Murakami; Jiro Ohuchida; Hidetoshi Eguchi; Hiroaki Nagano; Junichi Sakamoto; Hiroki Yamaue
Journal:  Clin Exp Gastroenterol       Date:  2020-10-19

3.  Acceleration of small bowel motility after oral administration of dai-kenchu-to (TJ-100) assessed by cine magnetic resonance imaging.

Authors:  Akitoshi Inoue; Akira Furukawa; Hiroshi Yamamoto; Shinichi Ohta; Nguyen Dai Hung Linh; Tulyeubai Syerikjan; Sachiko Kaida; Tsuyoshi Yamaguchi; Satoshi Murata; Toru Obata; Masaji Tani; Kiyoshi Murata
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

4.  Time-, Sex-, and Dose-Dependent Alterations of the Gut Microbiota by Consumption of Dietary Daikenchuto (TU-100).

Authors:  Jun Miyoshi; Kentaro Nobutani; Mark W Musch; Daina L Ringus; Nathaniel A Hubert; Masahiro Yamamoto; Yoshio Kase; Mitsue Nishiyama; Eugene B Chang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-22       Impact factor: 2.629

Review 5.  Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto.

Authors:  Toru Kono; Mitsuo Shimada; Masahiro Yamamoto; Atushi Kaneko; Yuji Oomiya; Kunitsugu Kubota; Yoshio Kase; Keiko Lee; Yasuhito Uezono
Journal:  Front Pharmacol       Date:  2015-08-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.